Skip to Content


Oversight of Laboratory Developed Tests; Public Meeting; Reopening of the Comment Period

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble


Food and Drug Administration, HHS.


Notice; reopening of the comment period.


The Food and Drug Administration (FDA) is reopening until September 15, 2010, the comment period for the notice that published in the Federal Register of Thursday, June 17, 2010 (75 FR 34463). In the notice, FDA requested input and comments from interested stakeholders on the agency's oversight of laboratory developed tests (LDTs). FDA is reopening the comment period to update comments and to receive any new information.


Submit either electronic or written comments and information by September 15, 2010.


Submit electronic comments or information to Submit written comments or information to the Division of Dockets Management (HFA-305), Food and Drug Administration, Start Printed Page 512815630 Fishers Lane, rm. 1061, Rockville, MD 20852.

Start Further Info


Katherine Serrano, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, rm. 5613, Silver Spring, MD 20993, 301-796-6652, email:

End Further Info End Preamble Start Supplemental Information


I. Background

In the Federal Register of June 17, 2010 (75 FR 34463), FDA published a notice announcing a public meeting on July 19 and 20, 2010, and the opening of a public docket to seek input and comments from interested stakeholders to discuss the agency's oversight of LDTs. Interested persons were originally given until August 15, 2010, to comment on information.

II. Request for Comments

Following publication of the June 17, 2010, notice, FDA received a request to allow interested persons additional time to comment. The requester asserted that the initial time period was insufficient to respond fully to FDA's specific requests for comments and to allow potential respondents to thoroughly evaluate and address pertinent issues.

III. How to Submit Comments

Interested persons may submit to the Division of Dockets Management (see ADDRESSES) either electronic or written comments regarding this document. It is only necessary to send one set of comments. It is no longer necessary to send two copies of mailed comments. Identify comments with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.

Start Signature

Dated: August 13, 2010.

Leslie Kux,

Acting Assistant Commissioner for Policy.

End Signature End Supplemental Information

[FR Doc. 2010-20489 Filed 8-18-10; 8:45 am]